Hudson Valley Investment Advisors’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$11.5M Sell
45,583
-69
-0.2% -$14.8K 1.39% 17
2026
Q1
$9.93M Sell
45,652
-3,094
-6% -$686K 1.29% 19
2025
Q4
$11.1M Sell
48,746
-1,944
-4% -$443K 1.23% 20
2025
Q3
$11.7M Sell
50,690
-604
-1% -$123K 1.22% 20
2025
Q2
$9.52M Buy
51,294
+2,704
+6% +$503K 1.04% 25
2025
Q1
$10.2M Sell
48,590
-4,983
-9% -$969K 1.22% 24
2024
Q4
$9.52M Sell
53,573
-3,801
-7% -$699K 1.08% 30
2024
Q3
$11.3M Buy
57,374
+4,685
+9% +$874K 1.25% 23
2024
Q2
$8.51M Sell
52,689
-1,503
-3% -$249K 1.11% 29
2024
Q1
$9.87M Buy
54,192
+6,053
+13% +$1.04M 1.18% 25
2023
Q4
$7.77M Buy
48,139
+1,440
+3% +$210K 1.06% 27
2023
Q3
$6.96M Buy
46,699
+3,473
+8% +$510K 0.98% 31
2023
Q2
$5.82M Buy
43,226
+867
+2% +$127K 0.79% 40
2023
Q1
$6.75M Sell
42,359
-647
-2% -$98.9K 0.94% 31
2022
Q4
$6.95M Buy
43,006
+1,511
+4% +$232K 1.05% 29
2022
Q3
$5.57M Buy
+41,495
New +$5.95M 0.89% 33

Other funds holding ABBV

Hudson Valley Investment Advisors's ABBV Position: Q2 2026 in Review

Hudson Valley Investment Advisors reduced its AbbVie (ABBV) stake by 0.15% in Q2 2026, selling an estimated $14.8K and leaving 45,583 shares worth $11.5M. The position accounts for 1.39% of the portfolio, ranked #17.

Hudson Valley Investment Advisors first reported a position in ABBV in Q3 2022 and has held it in 16 quarters since. The position peaked at $11.7M in Q3 2025. 2,113 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Hudson Valley Investment Advisors held 45,583 shares of AbbVie worth $11.5M as of Q2 2026.
  • Hudson Valley Investment Advisors sold 69 AbbVie shares in Q2 2026, an estimated $14.8K.
  • AbbVie made up 1.39% of Hudson Valley Investment Advisors's portfolio in Q2 2026, its #17 holding.
  • Hudson Valley Investment Advisors first reported a position in AbbVie in Q3 2022 and has held it in 16 quarters since.
  • Hudson Valley Investment Advisors's AbbVie position peaked at $11.7M in Q3 2025.
  • 2,113 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Hudson Valley Investment Advisors's 13F filing for Q2 2026, filed 21 Jul 2026.